Skip to main content

FOR US HEALTHCARE PROFESSIONALS ONLY

TYVASO and TYVASO DPI are approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise.

REDUCING STRAIN ON THE HEART

NT-proBNP blood test

PH-ILD can put strain on your heart. NT-proBNP is a measure of strain on the heart and can be detected by a blood test. Your doctor can check your NT-proBNP levels over time to see how the strain on your heart may be changing. If the numbers are higher, there is more strain on the heart; if the numbers are lower, there is less strain on the heart.

TYVASO has been shown to reduce strain on the heart

At week 16 of the clinical study, patients who took TYVASO had less strain on the heart (NT-proBNP decreased by 15%), while patients who took placebo had more strain on the heart (NT-proBNP increased by 46%).

NT-proBNP level reduction in 16 week clinical studyNT-proBNP level reduction in 16 week clinical study
TYVASO has been shown to reduce the risk of PH-ILD getting worse.

NOW APPROVED—TYVASO DPI FITS IN THE PALM OF YOUR HAND

Ask your healthcare provider about the
Dry Powder Inhaler (DPI) option now approved for TYVASO®.

bubbles pattern
hand holding dpi devicebubbles pattern

See how simple TYVASO DPI is to use.

bubbles pattern